+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Paediatric Vaccine market (2021-2026) by Type, Technology, Application, Geography and the Impact of COVID-19 with Ansoff Analysis, Infogence Competitive Quadrant

  • PDF Icon


  • 146 Pages
  • April 2021
  • Region: Global
  • Infogence Global Research
  • ID: 5317161
Early vaccination helps to develop antibodies against several infectious diseases. Vaccinations are prescribed in different age groups. Early immunization can prevent 2 million to 3 million deaths every year. Vaccine-preventable diseases are known to have a costly impact leading to frequent hospitalizations and death in certain cases. As per the UNICEF, an estimated 14 million infants have not received the vaccination, and around 85 countries are still to receive the Global Vaccination Action Plan (GVAP).

Pediatric vaccines are administered to an infant in its pediatric stage i.e. (0-12). These vaccines include the DTP vaccine, MMR vaccine, polio vaccine, and meningococcal vaccine, etc. They are usually administered at regular intervals to fight against infections and seasonal variations. In today's dynamic business environment, there has been an excessive focus on R&D for the vaccines and the maximum coverage of the infant vaccines. With the increasing focus of the Government on vaccination, pediatric vaccines have increased over time. Besides, technologies such as synthetic vaccinology and platform manufacturing can help speed up the processing time taken to manufacture the new vaccines. This can additionally also help in improving the vaccination rate. Healthcare associations like the UNICEF or the WHO actively promote immunization campaigns, especially in developing countries.

The Global Pediatric Vaccines Market is estimated to be USD 49.7 Bn in 2021 and is expected to reach USD 82.35 Bn by 2026, growing at a CAGR of 10.6%.

Certain factors, such as the rising number of chronic diseases across the globe along with the global initiatives taken towards vaccine production for rare diseases, have been major drivers of growth for the pediatric market. Increasing cases of invasive cervical cancer are also expected to fuel the growth of the market. Such cancer types can be prevented through the HPV vaccine and regular cervical screenings between the ages of 9-12. Additionally, increasing awareness about the importance of pediatric vaccination in the prevention of diseases is expected to fuel market growth.

However, the costs attached to immunization and the accessibility restrains the growth of this market. The increasing availability of biosimilar at low rates is also creating hindrances for the market.

Market Dynamics

  • Rising Burden of Chronic Diseases
  • Technological Advancements in Vaccines
  • Favorable Government Support in Promoting Vaccination

  • Cost of Immunization
  • Low Medical Coverage and Healthcare Services in Low - and Middle-income Countries

  • Growing Importance and Awareness of Immunization
  • Rising Number of Collaborations, Expansions, and Mergers

  • Stringent Regulatory Compliance in the Development of Vaccines
  • Refusal of Immunization due to Low Awareness and Vaccines Shortages

  • The Emergence of a Paediatric Vaccine as a Therapeutic Agent Against Cervical Cancer

Segments Covered

By Vaccine Type, the Monovalent Vaccine is estimated to account for the fastest-growing segment during the forecast period. It has been noted that many of the newly approved pediatric vaccines, as well as existing pediatric vaccines today, are monovalent vaccines, thus adding to the market growth.

By Technology, Conjugate/Subunit Vaccines are estimated to be the fastest-growing segment during the forecast period. It is due to the high immune response provided to the body by the vaccine to fight against specific types of microorganisms. Thus, the rising number of regulatory approvals for conjugate vaccines have been major promoters of growth.

By Application, The Infectious Diseases Segment holds the largest share due to rising global awareness about immunization against infectious diseases that cause death. An increase in the incidence of diseases, such as chickenpox, typhoid, cholera, measles, and hepatitis, in infants, results in high demand for immunization, which positively impacts the market.

By Geography, North America is anticipated to lead the market. The factors attributed to the growth of the market are the growing incidences of infectious diseases, availability of reimbursement schemes, new product approvals, and high spending and initiatives taken by the Government in the healthcare industry. The European market is also expected to grow due to the ease of operability, efficient resource planning, a large number of pharmaceutical manufacturers, and rising government funding.

The Global Paediatric Vaccine market is further segmented on the basis of Type, Technology, Application, and Geography.

Global Paediatric Vaccines Market, By Vaccine Type
  • Introduction
  • Monovalent
  • Multivalent

Global Paediatric Vaccines Market, By Technology
  • Introduction
  • Live Attenuated
  • Inactivated
  • Subunits
  • Toxoid
  • Conjugate
  • Other Technologies

Global Paediatric Vaccines Market, By Application
  • Introduction
  • Infectious Diseases
  • Cancer
  • Allergies
  • Other Applications

Global Paediatric Vaccines Market, By Geography
  • Introduction
  • North America
  • South America
  • Europe
  • Asia Pacific
  • The Middle East and Africa

Company Profiles

Some of the companies covered in this report are Sanofi S.A., GlaxoSmithKline plc, Merck & Co., Inc., Pfizer Inc., Grifols, Serum Institute of India Pvt. Ltd., AstraZeneca, Cadila Healthcare Ltd, Indian Immunologicals Limited, and CSL Limited.

Competitive Quadrant

The report includes a Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

  • Lions: Represents companies with a strong foothold in the market, with the highest market share, large investments in technologies, new products.
  • Bulls: Companies that are medium in size competing with their USPs, growing companies with proven market share.
  • Rabbits: Small companies but growing rapidly, constantly improving their offerings in the market
  • Tortoise: Companies which are slow in growth, having a long legacy, and stable or negative in performance

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Paediatric Vaccines Market.
  • The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes in-depth market analysis using Porter’s 5 force model and the Ansoff Matrix. The impact of Covid-19 on the market is also featured in the report.
  • The report also contains the competitive analysis using the Competitive Quadrant, the analyst's Proprietary competitive positioning tool.

Report Highlights:
  • A complete analysis of the market including parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market
Frequently Asked Questions about the Global Paediatric Vaccine Market

What is the estimated value of the Global Paediatric Vaccine Market?

The Global Paediatric Vaccine Market was estimated to be valued at $49700 Million in 2021.

What is the growth rate of the Global Paediatric Vaccine Market?

The growth rate of the Global Paediatric Vaccine Market is 10.6%, with an estimated value of $82350 Million by 2026.

What is the forecasted size of the Global Paediatric Vaccine Market?

The Global Paediatric Vaccine Market is estimated to be worth $82350 Million by 2026.

Who are the key companies in the Global Paediatric Vaccine Market?

Key companies in the Global Paediatric Vaccine Market include GlaxoSmithKline PLC, Indian Immunologicals Limited, AstraZeneca, Merck & Co. Inc., Mitsubishi Tanabe Pharma Corporation, Pfizer Inc., Sanofi SA, Seqirus (CSL Limited) and Grifols.

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Shareholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.3 Market Size Estimation
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
4 Market Overview
4.1 Introduction
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Challenges
4.3 Trends
5 Market Analysis
5.1 Porter’s Five Forces Analysis
5.2 Impact of COVID-19
5.3 Ansoff Matrix Analysis
6 Global Paediatric Vaccines Market, By Vaccine Type
6.1 Introduction
6.2 Monovalent
6.3 Multivalent
7 Global Paediatric Vaccines Market, By Technology
7.1 Introduction
7.2 Live Attenuated
7.3 Inactivated
7.4 Subunits
7.5 Toxoid
7.6 Conjugate
7.7 Other Technologies
8 Global Paediatric Vaccines Market, By Application
8.1 Introduction
8.2 Infectious Disease
8.3 Cancer
8.4 Allergies
8.5 Other Applications
9 Global Paediatric Vaccines Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 South America
9.3.1 Brazil
9.3.2 Argentina
9.4 Europe
9.4.1 UK
9.4.2 France
9.4.3 Germany
9.4.4 Italy
9.4.5 Rest of Europe
9.5 Asia-Pacific
9.5.1 China
9.5.2 Japan
9.5.3 India
9.5.4 Australia
9.5.5 Rest of APAC
9.6 The Middle East and Africa
10 Competitive Landscape
10.1 Competitive Quadrant
10.2 Market Share Analysis
10.3 Competitive Scenario
10.3.1 Mergers & Acquisitions
10.3.2 Agreements, Collaborations, & Partnerships
10.3.3 New Product Launches & Enhancements
10.3.4 Investments & Fundings
11 Company Profiles
11.1 GlaxoSmithKline PLC
11.2 Indian Immunologicals Limited
11.3 AstraZeneca
11.4 Merck & Co. Inc.
11.5 Mitsubishi Tanabe Pharma Corporation
11.6 Pfizer Inc.
11.7 Sanofi SA
11.8 Seqirus (CSL Limited)
11.9 Sinovac Biotech Ltd
11.10 Grifols
11.11 Serum Institute of India Pvt. Ltd.
11.12 Cadila Healthcare Ltd
11.13 Panacea Biotec
11.14 Daiichi Sankyo
11.15 Johnson & Johnson
11.16 Astellas Pharma
11.17 Bristol-Myers Squibb
11.18 Novo Nordisk A/S
11.19 Eli Lilly and Company
11.20 Abbott Laboratories
12 Appendix
12.1 Questionnaire

Companies Mentioned

  • GlaxoSmithKline PLC
  • Indian Immunologicals Limited
  • AstraZeneca
  • Merck & Co. Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Pfizer Inc.
  • Sanofi SA
  • Seqirus (CSL Limited)
  • Sinovac Biotech Ltd
  • Grifols
  • Serum Institute of India Pvt. Ltd.
  • Cadila Healthcare Ltd
  • Panacea Biotec
  • Daiichi Sankyo
  • Johnson & Johnson
  • Astellas Pharma
  • Bristol-Myers Squibb
  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Abbott Laboratories